Divi's Laboratories Q4 FY26 results (Jan–Mar 2026) and concall

Healthcare · Concall AI · Call held 23 May 2026

Company page: Divi's Laboratories share price, financials & guidance record

Divi's Laboratories reported strong financial performance for FY26, with double-digit growth in revenue and profit after tax, driven by robust Nutraceuticals sales and improved operational efficiency. The company continued its strategic investments in capacity expansion, capitalizing ₹1,544 crores in assets. However, the business navigated challenges from geopolitical tensions, increased freight rates, and raw material price volatility, while managing pricing pressures in the generics segment.

You’re reading a preview. Opening the full call uses 1 concall credit.

What they filed

Q4 FY26: revenue up 10.1%, net profit up 13.3% against the same quarter last year.

₹ Cr · quarterly

Line item	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26	Q3 FY26	Q4 FY26
Revenue	2,302	2,297	2,536	2,357	2,660 +16%	2,578 +12%	2,793 +10%
Expenses	1,573	1,550	1,655	1,614	1,765	1,671	1,850
EBITDA	729	747	881	743	895 +23%	907 +21%	943 +7%
Margin	32%	33%	35%	32%	34%	35%	34%
Other income	105	82	87	119	146	13	154
Interest	1	0	0	3	8	6	6
Depreciation	98	99	107	112	113	116	120
Profit before tax	735	730	861	747	920 +25%	798 +9%	971 +13%
Tax rate	30%	19%	23%	25%	24%	25%	22%
Net profit	518	594	667	557	696 +34%	598 +1%	756 +13%
EPS	19.51	22.38	25.13	20.98	26.22	22.53	28.48

How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.

What they filed

More Healthcare earnings calls